CMS Scraps ‘Most Favored Nation’ Rule To Lower Medicare Part B Drug Costs

US Centers For Medicare and Medicaid Services doesn’t tip its hand on what, if anything, might replace the rule but says it is exploring ways to lower spending on Medicare Part B drugs.

Infusion of a hospital
Trump-Era Plan To Lower Cost Of Physician Administered Drugs Scuttled

The US Centers for Medicare and Medicaid Services aims to withdraw the Trump administration's plan for a demonstration project to lower Medicare spending on high-cost Part B drugs by matching reimbursement rates to the lowest price found in certain countries abroad, also known as the "most favored nation" policy. 

The move comes less than a month before the Biden administration is slated to outline some of its own drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

Pharma Cooperating With Trump On Direct Sale To Consumers, Pfizer CEO Says

 

Pfizer is in active discussions with Trump on MFN pricing and collaborating with peers on direct sales as an approach to lower drug prices, CEO Albert Bourla said.

Cuban: Drugmakers Are More Afraid of PBMs Than Trump

 
• By 

The billionaire investor said during a recent conference that brand drug manufacturers want to work with his Cost Plus Drug Co., but are afraid the PBMs will retaliate.

Most Favored Nation Pricing: Trump Ups Pressure On Voluntary Action, Clarifies Demands

 

The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.

340B Rebate Model Gets HRSA Endorsement; Pilot Program Limited To Medicare Negotiated Drugs

 
• By 

Pilot is harbinger of greater transparency in the 340B program. But rebates may only be denied by manufacturers for overlap with Medicare negotiated prices, not for issues like diversion that have driven recent lawsuits.

More from Market Access

Faster HTA Reviews & Pricing Reform Could Help Fix Canada’s Drug Access Woes

 

Canadian politicians must “move quickly” to introduce policies that will speed up access to medicines, such as by broadening criteria for the temporary reimbursement of medicines, the Canadian Chamber of Commerce says.

Most Favored Nation Pricing: Trump Ups Pressure On Voluntary Action, Clarifies Demands

 

The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.

340B Rebate Model Gets HRSA Endorsement; Pilot Program Limited To Medicare Negotiated Drugs

 
• By 

Pilot is harbinger of greater transparency in the 340B program. But rebates may only be denied by manufacturers for overlap with Medicare negotiated prices, not for issues like diversion that have driven recent lawsuits.